Cargando…
Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients’ quality of life (QoL) following different types of nephron-sparing treatments remains unclear. PURPOSE: To investigate the quality of life and complications after nephron-sparin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725354/ https://www.ncbi.nlm.nih.gov/pubmed/34983648 http://dx.doi.org/10.1186/s13643-021-01868-2 |
_version_ | 1784626098695307264 |
---|---|
author | Junker, Theresa Duus, Louise Rasmussen, Benjamin S. B. Azawi, Nessn Lund, Lars Graumann, Ole Nørgaard, Birgitte |
author_facet | Junker, Theresa Duus, Louise Rasmussen, Benjamin S. B. Azawi, Nessn Lund, Lars Graumann, Ole Nørgaard, Birgitte |
author_sort | Junker, Theresa |
collection | PubMed |
description | BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients’ quality of life (QoL) following different types of nephron-sparing treatments remains unclear. PURPOSE: To investigate the quality of life and complications after nephron-sparing treatment of renal cell carcinomas of stage T1. MATERIALS AND METHODS: A systematic search of six databases was carried out. We included studies that reported the quality of life and complications in patients aged 18 years or older following nephron-sparing treatment of renal cell carcinoma stage T1. The quality assessment was performed using the Critical Appraisal Skills Programme (CASP) checklist for cohort studies and the CASP Randomized Controlled Trial Checklist. Data were analyzed using a narrative approach. RESULTS: Eight studies were included, six of which investigated QoL after partial nephrectomy and two after ablation therapies. Seven studies reported complications. Three studies reported higher QoL scores after partial nephrectomy compared to radical nephrectomy. Two studies showed that QoL increased or returned to baseline levels up to 12 months following partial nephrectomy. One study reported a gradual increase in QoL after radiofrequency ablation, and one study reported that all patients recovered to baseline QoL following cryoablation. Across studies, we found a complication rate up to 20% after partial nephrectomy and up to 12.5% after ablation therapy. CONCLUSIONS: The results of this systematic review suggest that nephron-sparing treatment appears to be superior or comparable to other treatment alternatives with regard to QoL outcomes. Additionally, based on the studies included in this review, partial nephrectomy appears to have a higher complication rate compared with ablation therapies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020155594 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-021-01868-2. |
format | Online Article Text |
id | pubmed-8725354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87253542022-01-06 Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review Junker, Theresa Duus, Louise Rasmussen, Benjamin S. B. Azawi, Nessn Lund, Lars Graumann, Ole Nørgaard, Birgitte Syst Rev Research BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients’ quality of life (QoL) following different types of nephron-sparing treatments remains unclear. PURPOSE: To investigate the quality of life and complications after nephron-sparing treatment of renal cell carcinomas of stage T1. MATERIALS AND METHODS: A systematic search of six databases was carried out. We included studies that reported the quality of life and complications in patients aged 18 years or older following nephron-sparing treatment of renal cell carcinoma stage T1. The quality assessment was performed using the Critical Appraisal Skills Programme (CASP) checklist for cohort studies and the CASP Randomized Controlled Trial Checklist. Data were analyzed using a narrative approach. RESULTS: Eight studies were included, six of which investigated QoL after partial nephrectomy and two after ablation therapies. Seven studies reported complications. Three studies reported higher QoL scores after partial nephrectomy compared to radical nephrectomy. Two studies showed that QoL increased or returned to baseline levels up to 12 months following partial nephrectomy. One study reported a gradual increase in QoL after radiofrequency ablation, and one study reported that all patients recovered to baseline QoL following cryoablation. Across studies, we found a complication rate up to 20% after partial nephrectomy and up to 12.5% after ablation therapy. CONCLUSIONS: The results of this systematic review suggest that nephron-sparing treatment appears to be superior or comparable to other treatment alternatives with regard to QoL outcomes. Additionally, based on the studies included in this review, partial nephrectomy appears to have a higher complication rate compared with ablation therapies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020155594 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-021-01868-2. BioMed Central 2022-01-04 /pmc/articles/PMC8725354/ /pubmed/34983648 http://dx.doi.org/10.1186/s13643-021-01868-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Junker, Theresa Duus, Louise Rasmussen, Benjamin S. B. Azawi, Nessn Lund, Lars Graumann, Ole Nørgaard, Birgitte Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review |
title | Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review |
title_full | Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review |
title_fullStr | Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review |
title_full_unstemmed | Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review |
title_short | Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review |
title_sort | quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage t1—a systematic review |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725354/ https://www.ncbi.nlm.nih.gov/pubmed/34983648 http://dx.doi.org/10.1186/s13643-021-01868-2 |
work_keys_str_mv | AT junkertheresa qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview AT duuslouise qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview AT rasmussenbenjaminsb qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview AT azawinessn qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview AT lundlars qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview AT graumannole qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview AT nørgaardbirgitte qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview |